

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

IM-9

RRID:CVCL_1305

Type: Cell Line

Proper Citation

RRID:CVCL_1305

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1305

Proper Citation: RRID:CVCL_1305

Description: Cell line IM-9 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Female

Defining Citation: [PMID:1366653](#), [PMID:2836165](#), [PMID:7579375](#), [PMID:8139288](#), [PMID:9290701](#), [PMID:9510473](#), [PMID:10516762](#), [PMID:10936422](#), [PMID:20164919](#), [PMID:20454443](#), [PMID:27397505](#), [PMID:29892436](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misclassified. Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=10516762)..

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: IM-9

Synonyms: IM 9, IM9, GM04680

Cross References: BTO:BTO_0002897, CLO:CLO_0006703, CLO:CLO_0006705, CLO:CLO_0019036, CLDB:cl2635, CLDB:cl2636, CLDB:cl2637, CLDB:cl4962, CLDB:cl5210, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, ATCC:CCL-159, BCRC:60115, BioGRID_ORCS_Cell_line:899, BioSample:SAMN03471460, BioSample:SAMN03472807, CCRID:1102HUM-NIFDC00064, Cell_Model_Passport:SIDM00632, ChEMBL-Cells:ChEMBL3307412, ChEMBL-

Targets:CHEMBL614584, CLS:302151, Coriell:GM04680, Cosmic:753563, Cosmic:888021, Cosmic:919137, Cosmic-CLP:753563, DepMap:ACH-002247, DSMZ:ACC-117, DSMZCellDive:ACC-117, ECACC:86051302, EGA:EGAS00001000978, GDSC:753563, GEO:GSM1374572, GEO:GSM1669932, IARC_TP53:21395, ICLC:HTL99009, IZSLER:BS TCL 98, JCRB:IFO50025, JCRB:JCRB0024, KCLB:10159, LINCS_LDP:LCL-1958, Lonza:9, Pharmacodb:IM9_656_2019, PRIDE:PXD030304, PubChem_Cell_line:CVCL_1305, Wikidata:Q54897504

ID: CVCL_1305

Record Creation Time: 20220427T220632+0000

Record Last Update: 20260920T004155+0000

Ratings and Alerts

No rating or validation information has been found for IM-9.

Warning: Problematic cell line: Misclassified. Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=10516762).

Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misclassified. Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=10516762)..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zhao J, et al. (2026) Construction and experimental verification of a prognostic model based on tumor-infiltrating lymphocytes related genes (TILRGs) in diffuse large B-cell lymphoma. SLAS technology, 39, 100425.

Venetz-Arenas N, et al. (2025) Development of DARPin T cell engagers for specific targeting of tumor-associated HLA/peptide complexes. iScience, 28(12), 113926.

Luo Y, et al. (2024) Heparan sulfate promotes TRAIL-induced tumor cell apoptosis. eLife, 12.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer cell, 41(12), 2136.

Buonato JM, et al. (2022) Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain. Molecular cancer

therapeutics, 21(7), 1171.

Kosako H, et al. (2022) Allosteric Inhibition of c-Abl to Induce Unfolded Protein Response and Cell Death in Multiple Myeloma. *International journal of molecular sciences*, 23(24).

Yamashita Y, et al. (2020) Targeting Adaptive IRE1 α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib. *International journal of molecular sciences*, 21(17).